**Deadline 2020, October 31st**

***MATWIN*** *is a French open-innovation platform aiming at selecting and supporting the maturation of oncology innovative research projects to optimise their transfer potential with partners (big companies, biotechs, investors, etc.). The present form should describe your project from a translational point of view. To access our support, the project will first be reviewed by the MATWIN* [*International Board*](https://matwin.fr/en/matwin-international-board/)*. For assistance do not hesitate to ask your Technology Transfer Office and/or institutional partner (Cancéropôle, research institution…) or MATWIN.*

**Research Project**

|  |  |
| --- | --- |
| **Title** |  |
| **Acronym** |  |
| **Key words** |  |

**Project Coordinator**

|  |  |
| --- | --- |
| **Title; Name** |  |
| **Position** |  |
| **Lab / Organisation** |  |
| **Address** |  |
| **E-mail** |  | **Phone / Mobile** |  |

**For European project outside France – French established collaborator**

|  |  |
| --- | --- |
| **Collaboration type** |  |
| **Title; Name** |  |
| **Position** |  |
| **Lab / Organisation** |  |
| **Address** |  |
| **E-mail** |  | **Phone / Mobile** |  |

**Technology Transfer Office (*for academic team)* / Patent Office (*for start-up)***

|  |  |
| --- | --- |
| **Name** |  |
| **Contact name** |  |
| **Address** |  |
| **E-mail** |  | **Phone / Mobile** |  |

1. **ABSTRACT (400 words MAX - NOT CONFIDENTIAL)**

(Summarize your project as NOT confidential, to allow diffusion to peers without jeopardizing proprietary information). **Only the abstract must be considered as NOT confidential.**

👉 Please, note that your summary must answers the followings and indicate your French established collaboration *(for European project outside France only)*:

1. Application domain

2. Innovative component / Competitive differentiator

3. Objectives

4. Concept

5. Methodology

6. Expected results

7. Impact

1. **INTELLECTUAL PROPERTY**

**Patent 🡪 one table for each patent, filed or granted**

|  |  |
| --- | --- |
| Patent title |  |
| Date of patent filing |  |
| Patent co-owners (institutions) |  |
| National / PCT / WO number |  |
| Freedom To Operate ? Y/N - Patent officer(1 page summary to be joined) |  |
| Potential agreement (license) limiting use of IP? Involved parties & type of agreement? |  |

1. **SCIENTIFIC PROJECT (4-5 PAGES MAX - CONFIDENTIAL)**
* **Context and background**: Describe succinctly the context and the goal to be reached **(A HALF PAGE MAX including the 4-5 more relevant publication references)**
* **Current stage of development:** Describe the project’s development stage relative to the goal to be reached **(bullet points)**, including **the essential / relevant data** justifying your claims regarding the mechanism of action, the proof of concept, benchmarking, etc. with **3-4 figures** of the most relevant and differentiating data. **(3-4 PAGES MAX)**
* **Research and development plan**: List the main steps / GANTT Chart with workpackages & GO/No GO to achieve the final goal **(bullet points - A HALF PAGE MAX)**

# UNDERTAKING

## Project Leader and TTO representative

*The parties, undersigned confirm that they (i) completed all sections and that all information given in this form is complete and true, (ii) obtained the agreement of collaborators and institutional contacts for their participation (iii)* ***fully agree with the Charter on Rights and Duties of MATWIN applicants*** *(included appendix). They authorise MATWIN to share this application form for assessment, under confidentiality agreement condition for each person who accesses this as described in MATWIN Charter (see appendix).*

|  |  |
| --- | --- |
| **Name of the leader applicant :** | **Name of the TTO legal representative :** |
| **Date and Signature** | **Date and Signature** |

File to be sent to: emmanuel.conseiller@matwin.fr before October 31st, 2020

**APPENDIX – IMPORTANT (to be read before applying)**

**MATWIN Charter**

**Rights and Duties**

MATWIN, a fully owned subsidiary of UNICANCER group, is the service company supporting the MATWIN Programme which relies on a collaborative process with major pharmaceutical and diagnostic companies and a team of international scientific experts to accelerate research and innovation transfer of early stage innovation in oncology with high transfer potential.

MATWIN, acting like a mutualized projects sourcing platform for industrial partners, is fully committed to increase the international attractiveness of research in oncology and to identify and qualify the projects in order to connect them with the most appropriate/suitable partners willing to support them during their industrial maturation stage.

MATWIN’s operational decisions rely on an International multidisciplinary Board which meets annually (referred to hereinafter as “MATWIN Board”) gathering key opinion leaders in oncology from all Europe and industrial representatives from the MATWIN industrial partners. This committee is responsible for assessing and recommending the submitted projects and after each annual Board meeting, every industrial partner has a prior right to express an interest on developing (or co-developing) projects.

When applying to MATWIN, the candidates (and their Technology Transfer Office representatives when applicable) fully agree with the following Rights and Duties of MATWIN and applicants. They also agree to sign, if eligible to the MATWIN support, to sign an agreement with MATWIN addressing the different items below.

**MATWIN’s duties**

1. **Best practices**

MATWIN undertakes to implement the MATWIN Programme according to the best practices in order to meet the requirements of the technology transfer to the preclinical proof of concept stage.

MATWIN undertakes to make every effort with the support of the major research and care institutions, to:

* + Identify the best projects in oncology from the whole European territory.
	+ Help to structure these projects in accordance with the industrial partners’ requirements.
	+ Shorten as most as possible the period of time between the patent and the transfer in order to accelerate the availability of possible therapeutic innovations.
1. **Applicants visibility**

MATWIN undertakes to give the best visibility to every submitted project in order to reinforce sourcing opportunities.

MATWIN undertakes to raise greater awareness of every submitted project by providing access to the industrial partners represented at the highest level on the MATWIN Board (International Global executive, Early development, drug discovery or oncology position) of all the necessary documents to ease its assessment.

MATWIN undertakes to provide all necessary efforts to facilitate intermediation between submitted projects after their presentation to the MATWIN Board by requesting from the industrial Board members and partners (the 'Partners') to indicate a potential prior interest on projects submitted to the MATWIN Board.

In case of an interest on one or several projects, MATWIN Partners may mandate the platform to provide a support on coordinating and following the exchanges with the applicants and IP owners (and/or their legal representatives) until the signature of a potential partnership or transfer agreement regarding the concerned project(s). On top of these, MATWIN undertakes to provide all necessary efforts all along the programme and after to facilitate intermediation with any partner that may benefit the project (Technology Transfer Offices, Biotech companies, Investors …).

1. **Confidentiality**

MATWIN undertakes ensuring confidentiality related to every submitted project by prohibiting internal and external communication of any confidential document without the applicant's prior written approval.

Generally speaking, each actor of the MATWIN programme (MATWIN employees, experts, coaches, members and invited members of the MATWIN Board) undertakes not to publish or disclose under no circumstances the confidential scientific or technical information and datas belonging to the applicants by signing a confidential agreement with MATWIN prior accessing to any of these information.

**The Applicant’s duties**

1. **Best practices and divulgation**

The applicant guarantees the accuracy of scientific data presented all along the MATWIN Programme as well as their origin.

According to MATWIN's confidentiality duties, the applicant undertakes providing all scientific information and datas all along the MATWIN process for an optimal assessment of the project. In case the applicant may refuse to share the expected scientific information and datas, he takes the risk of being excluded from the MATWIN Programme.

1. **Transparency / Information**

The applicant undertakes keeping MATWIN informed of any discussion and any agreement that may be initiated or signed as a (direct or indirect) consequence of the MATWIN Programme.

This encompasses:

* Maturation or extension of maturation programme agreed with a Technology Transfer Office
* Start-up creation
* Collaboration agreement, licensing agreement
* Funding agreement, fundraising, crowdfunding, etc.

The applicant undertakes facilitating the use by MATWIN of such information for advertising on and promoting the MATWIN Programme.

1. **Financial duties**
	1. **Reimbursement of MATWIN Programme costs**

The French applicants undertake to reimburse the overall cost of the support Programme they benefited from in case of any agreement that may be concluded as a direct or indirect consequence of the MATWIN Programme. This encompasses:

* Any agreement generating extra revenues for the project (licensing agreement -even optional- or transfer agreement)
* Funding agreement, fundraising, crowdfunding, etc.

The non-French European applicants having access to a specific support, thus undertake to reimburse the costs of the Programme they benefited from, according to final step reached within the MATWIN process, and regardless of the outcome of the project in the MATWIN process (successful or not).

The costs associated to the MATWIN support Programme are as follow :

* Written Board feedback post 1st pitch of preselection (alone) : 2.000 €
* Coaching - 2 sessions : Development plan review + Training before Board meeting (alone) : 4.000 €

If selected for the final Board meeting presentation, the overall cost of the MATWIN support is **10.000 € V.A.T** **excluded** (Board feedback post 1st pitch of preselection + coaching + Board meeting).

* 1. **Fees for success**

In case of any success as described previously (§ 3.1) that may be concluded as a direct consequence of the MATWIN Programme, generating a first phase of funding for the preclinical or clinical development of the project, and on top of reimbursement of the MATWIN Programme costs, the applicant (and its Technology Transfer Office when applicable) undertakes to pay success fees to MATWIN.

A direct consequence is defined as a MATWIN partner positioning who is:

* An already established partner of the MATWIN programme
* A partner proposed by MATWIN with whom the applicant was not already in touch with (or if in touch, with a different representative)

These success fees due to MATWIN will be negociated between MATWIN and the applicant (and its Technology Transfer Office when applicable) on the following basis:

- Between 1 and 250k€ of generated funding : 8% of the funding (up to 15k€)

- Between 251k€ and 500k€ of generated funding : 6% of the funding

- Over 501k€ of generated funding : a lump-sum payment of 30k€

The MATWIN Programme costs that have already been paid to MATWIN will be deducted from the success fees.

Pierre FUMOLEAU

MATWIN President

